Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial

Post hoc analysis (n=2258 of 8232) suggests patients with severe heart failure (HF) who received tis selective cardiac myosin activator experienced significant treatment benefit for primary end point (HR 0.80; 95% CI, 0.71-0.90) which was not evident in patients without severe HF

SPS commentary:

According to the editor’s note, findings from GALACTIC-HF trial were welcomed as a new treatment opportunity for patients with HF with reduced ejection fraction and introduced a new drug class, myotrope, to the vernacular of HF therapeutics. However, because the overall clinical benefits among the patients enrolled in the trial were quite modest (over median follow up of 21.8 months, primary-outcome event [composite first heart-failure event or death from cardiovascular causes] occurred in 37.0% with omecamtiv mecarbil and 39.1% placebo; HR 0.92; 95%, 0.86-0.99; p=0.03), a major question that emerged was which patients may derive clinically relevant benefits.

JAMA Cardiology

Resource links:

Editor's Note

GALACTIC-HF primary analysis